75909
document
Randomized trial of high-dose cytarabine versus amsacrine in acute myelogenous leukemia in relapse : a Leukemia Intergroup Study . Patients with acute myelogenous leukemia in relapse who were ineligible for further anthracycline therapy either because they were judged to be anthracycline resistant or had received the maximum doses were randomized to receive high-dose cytarabine ( 3 g/m2 every 12 hours for 6 days ) or amsacrine ( 75 mg/m2 daily for 7 days ) . The response rates in both groups were similar : three of 25 patients given high-dose cytarabine and three of 23 given amsacrine obtained complete remissions .
75910
Intervention_Pharmacological
cytarabine
75911
Intervention_Pharmacological
amsacrine
75912
Intervention_Pharmacological
anthracycline therapy
75913
Intervention_Pharmacological
anthracycline
75914
Intervention_Pharmacological
cytarabine
75915
Intervention_Pharmacological
amsacrine
75916
Intervention_Pharmacological
cytarabine
75917
Intervention_Pharmacological
amsacrine
75918
Outcome_Other
response rates
75919
Outcome_Other
complete remissions .
75920
Participant_Condition
acute myelogenous leukemia in relapse
75921
Participant_Condition
acute myelogenous leukemia in relapse
75922
Participant_Condition
ineligible for further anthracycline therapy
75923
Participant_Condition
anthracycline resistant
75924
Participant_Condition
had received the maximum doses
75925
Participant_Sample-size
25
75926
Participant_Sample-size
23